Blood-based CRC screening fits right in.
ShieldTM is a blood-based test that can be completed at any patient visit1,2
A blood-based approach is the patient-preferred screening option for CRC3*
This option fits into patients’ schedules and breaks through screening
barriers since it requires4
from family or work
It also fits right into a provider’s practiceIf providers can order a complete blood count for their patients, they’re equipped to order
a blood-based CRC screening test.3
Shield is now available to order
Shield detects CRC with high accuracy1,2,5
And advanced adenomas were detected with 20% sensitivity5†
These data add to a growing body of evidence that demonstrates the high sensitivity of our blood-based technology51,784 individuals were evaluated in 2021 using our blood-based screening technology in 2 studies, which were presented at ASCO and ACG.5,6,7‡
We are currently conducting a registrational trial, ECLIPSE, to further validate our technology8The trial aims to enroll ~13,000 patients (ages 45-84) at average risk for CRC.9
Sign up to receive the latest updates on ShieldTM
*In a study, patients who initially refused colonoscopy preferred screening with a blood-based test over a stool-based test 83% vs 15%, respectively.3
†In a study of 309 patients, sensitivity was 94% in Stages I-II, 86% in Stage III (91% overall), 20% in advanced adenomas, and specificity was 92%.5
‡2021 American Society of Clinical Oncology and 2021 American College of Gastroenterology.
§The assay is intended to be complementary to and not a replacement for current recommended colorectal cancer screening methods.
Patients with an abnormal blood-based screening result should be referred for colonoscopic evaluation.
- The assay is intended to be complementary to and not a replacement for current recommended colorectal cancer screening methods
- Patients with an "abnormal signal detected" Shield test result should be referred for colonoscopic evaluation
- A "normal signal detected" Shield test result does not preclude the presence of colorectal neoplasia, and patients should continue participating in guideline-recommended screening programs
- Shield was developed, and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high complexity clinical testing. This test has not been cleared or approved by the US FDA